Aclaris Therapeutics, Inc. (ACRS) · Nov 5, 2026 · Earnings

Aclaris earnings beat as clinical milestones stay on track

Beat — EPS $(0.12) vs ~$0.16 loss consensus; revenue $1.48M vs ~$1.23M

Aclaris earnings beat consensus while its clinical pipeline stays on schedule and cash now funds operations through the first half of 2029.

Aclaris is a clinical-stage immuno-inflammatory biotech moving from early proof-of-concept data toward several mid-stage catalysts, with ATI-052 now prioritized for eosinophilic esophagitis and bosakitug and modzatinib approaching important 2026 milestones. That setup was already largely visible before this release: ATI-052’s positive Phase 1b data were announced on October 27, while the prior quarter had already pointed to a second-half 2026 catalyst-heavy period.

The quarter beat the published bar, but the financial upside is secondary. Q3 revenue of $1.48 million exceeded published consensus of roughly $1.23 million, and the $0.12-per-share loss was narrower than the expected $0.16 loss. The beat is real, but revenue remains small and fell sharply year over year because the prior-year period included a Sun Pharma sales milestone.

Q3 2026Q3 2025Consensus
Revenue (Income Statement)$1.48M$3.30M$1.23M
Net loss (Income Statement)$18.51M$14.61M
Diluted EPS (Income Statement)$(0.12)$(0.12)$(0.16)
R&D expense (Income Statement)$16.07M$13.03M

Aclaris is spending more to move the pipeline forward. R&D rose to $16.1 million from $13.0 million as ATI-052 manufacturing and Phase 1b work, plus ATI-9494 development, increased spending. The larger loss and higher operating burn are therefore not a surprise in isolation, but they confirm that the company is converting its cash into broader clinical activity rather than approaching profitability.

The financing meaningfully reduces near-term funding risk, at the cost of dilution. After the October $50 million equity offering, management expects its cash, cash equivalents and marketable securities to fund operations through the first half of 2029, extending the prior end-2028 runway disclosed in the second-quarter update. The runway is a material improvement for a company entering multiple Phase 2 programs, although the offering added 7.8 million shares and warrants for another 6.5 million shares. 〔0〕

Most of the clinical headline is confirmation, not fresh information. The release reiterates the expected Q4 2026 bosakitug readout, November site activation for the modzatinib Phase 2b trial, and a Q4 2026 IND filing for ATI-9494. Those milestones strengthen execution credibility, but their timing was already communicated earlier, while the positive ATI-052 Phase 1b results had been disclosed days before this filing.

Bottom line: This is a modestly better-than-expected quarter that leaves Aclaris better funded and on schedule, rather than a fundamental rewrite of the biotech story. The real value of the filing is that it removes financing pressure ahead of the next clinical readouts; the most important efficacy news was already public.

### Sources:

-

-

-

What to watch next

Bosakitug Phase 2 results, expected Q4 2026

Original filing on SEC EDGAR

More Aclaris Therapeutics, Inc. news

Aclaris earnings beat as clinical milestones stay on track | ACRS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.